Bringing forward novel therapies for deadly resistant infections

iiCON partner Infex Therapeutics is progressing two novel therapeutics to tackle dangerous multi-drug resistant infections into clinical trials over the next 12 months as part of a programme supported by iiCON.
Based at Alderley Park, Infex translates research into novel therapies. The organisation acquires, develops and licenses innovative drugs to treat pandemic infections. It has developed a broad portfolio of new therapies to meet the rising burden of critical priority infectious diseases.

The company’s immune-infection RESP-X programme, which targets serious recurrent respiratory infections in patients with damaged lung functions, is expected to enter clinical trials in November 2021. Infex also plans to bring its resistance bypass therapy MET-X, which is currently undergoing manufacture, to clinical trials stage in late 2022 following toxicology screening and stability testing.

Working in partnership with fellow iiCON member, the Liverpool University Hospitals NHS Foundation Trust, Infex will leverage the clinical trials expertise at the NIHR Liverpool and Broadgreen Clinical Research Facility based at the Royal Liverpool University Hospital, where both therapies will be tested.

The two new medicines that Infex Therapeutics are progressing address dangerous multi-drug-resistant infections that are a key threat to global health. iiCON has supported Infex Therapeutics to accelerate these novel therapies to clinical trial stage – helping to expedite the journey of these much-needed new treatments to market.

Professor Janet Hemingway, iiCON Director, said:

Infex Therapeutics is working at the cutting-edge of drug discovery and development. We’re incredibly excited to see the outstanding progress they are making in the journey to develop these important novel therapies in response to the global antimicrobial resistance (AMR) challenge.

Supporting impactful co-innovation and collaboration between the NHS, industry, and academia is at the core of iiCON’s mission. Nurturing and enabling the innovation emerging from industry is key to our commitment to revitalise and strengthen the pipeline of new treatments for infectious diseases.